Abstract B7-H4 is a promising antibody-drug conjugate (ADC) target with high expression in several solid tumors and limited expression in normal tissue. B7-H4 negatively regulates T-cell function, and high expression of B7-H4 is associated with disease progression. AZD8205 (puxitatug samrotecan [Puxi-Sam]) is a novel B7-H4–directed ADC with a stable cleavable linker and a bystander-capable topoisomerase-1 (TOP1) inhibitor payload.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Jixin
Contact Jixin, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack